Article

Drug-related-lupus (DRL) is one of the manifestations of the drug-induced lupus (DIL). The aim of the present study was to analyze the clinical and immunological characteristics of patients with DRL, in order to summarize the manifestations, which worsen the prognosis of the disease. One hundred patients with systemic lupus erythematosus (SLE) were included in the study. Patients with DRL were 10 % of all screened lupus patients. In the patients observed by us, DRL had developed after the use of Cephalosporin (Rocephin), D-penicillamine, gold salts, Procainamide, beta-blockers, vaccines. The leading clinical manifestations in these patients were cutaneous and muscular ones, respectively, necrotizing vasculitis in five patients (50 %), myositis – in three patients (30 %), and in two patients (20 %) - generalized skin reaction, toxic epidermal necrolysis (Lyell syndrome). We found antinuclear antibodies (ANA) in nine patients (90 %) with DRL.